Exact Sciences Corporation

EXASintermediary

Exact Sciences is a molecular diagnostics company focused on cancer screening and precision oncology. Its Cologuard test has become the leading non-invasive colorectal cancer screening tool, and its multi-cancer early detection test aims to transform cancer diagnosis.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($2.8B)

Data statis (memuat keuangan langsung…)

Screening (Cologuard) (55%)

Precision Oncology (Oncotype DX) (35%)

Other / Pipeline (10%)

Komposisi segmen dan pelanggan utama

Detail produk

Cologuard (Colorectal Cancer)45%

Non-invasive stool DNA test for colorectal cancer screening

Oncotype DX (Breast Cancer)30%

Genomic test predicting breast cancer recurrence risk

Multi-Cancer Early Detection (MCED)10%

Blood-based test detecting multiple cancer types from a single draw

Hubungan Rantai Pasok

Mitra

Pfizer Inc.

Cancer screening combined with pharma treatment

Dampak: Low — co-marketing exploration

Eli Lilly and Company

Companion diagnostics for oncology drugs

Dampak: Low — diagnostic partnerships

Regeneron Pharmaceuticals

Genomic profiling for antibody therapies

Dampak: Low

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok Exact Sciences Corporation.

Info Perusahaan

Kantor Pusat

Madison, Wisconsin, USA

Didirikan

1995

Karyawan

7,200+

Situs Web

exactsciences.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor